
    
      This trial includes a screening visit (V1) and a monitoring visit (V2) and follow-up
      assessment. Visit 1 will be performed before performance of surgery to obtain informed
      consent and to assess patient eligibility. At Visit 2 monitoring visit after surgery)
      arterial blood glucose values will be monitored and subcutaneous sampling of ISF with
      microdialysis for glucose determination will be performed. Visit 2 will last from admittance
      to the ICU for 48 hours. In a follow-up assessment, two weeks after the end of visit 2,
      further clinical relevant data for the two week period after visit 2 will be collected.
    
  